Top-Rated Stocks NASDAQ:AXSM Axsome Therapeutics - AXSM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $68.70 -5.59 (-7.52%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$67.91▼$73.8350-Day Range$62.16▼$79.7252-Week Range$20.63▼$82.00Volume1.91 million shsAverage Volume916,556 shsMarket Capitalization$2.98 billionP/E RatioN/ADividend YieldN/APrice Target$108.15 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Axsome Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.83 Rating ScoreUpside/Downside57.4% Upside$108.15 Price TargetShort InterestBearish22.42% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.45Based on 8 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.43) to ($3.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.55 out of 5 starsMedical Sector108th out of 1,028 stocksPharmaceutical Preparations Industry45th out of 501 stocks 4.4 Analyst's Opinion Consensus RatingAxsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $108.15, Axsome Therapeutics has a forecasted upside of 57.4% from its current price of $68.70.Amount of Analyst CoverageAxsome Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted22.42% of the float of Axsome Therapeutics has been sold short.Short Interest Ratio / Days to CoverAxsome Therapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Axsome Therapeutics has recently increased by 5.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAxsome Therapeutics does not currently pay a dividend.Dividend GrowthAxsome Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAxsome Therapeutics has received a 69.80% net impact score from Upright. The largest positive contribution comes from its "Mental diseases" impact, which is driven by its "Clinical research services for mental health" product. See details.Environmental SustainabilityThe Environmental Impact score for Axsome Therapeutics is -1.03. Previous Next 3.0 News and Social Media Coverage News SentimentAxsome Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Axsome Therapeutics this week, compared to 5 articles on an average week.Search Interest43 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 95% compared to the previous 30 days.MarketBeat Follows15 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 15% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders26.00% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions59.71% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.43) to ($3.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Axsome Therapeutics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Axsome Therapeutics is -16.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAxsome Therapeutics has a P/B Ratio of 167.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Axsome Therapeutics (NASDAQ:AXSM) StockAxsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 which are being developed for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.Read More Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Stock News HeadlinesFebruary 1, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Shares Up 3.9% Following Analyst UpgradeJanuary 31, 2023 | finance.yahoo.comAxsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27February 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 31, 2023 | americanbankingnews.comShort Interest in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Rises By 5.2%January 30, 2023 | msn.comThe Latest Analyst Ratings for Axsome TherapeuticsJanuary 30, 2023 | americanbankingnews.comAxsome Therapeutics (NASDAQ:AXSM) Given New $86.00 Price Target at MizuhoJanuary 28, 2023 | americanbankingnews.comFY2022 Earnings Estimate for Axsome Therapeutics, Inc. (NASDAQ:AXSM) Issued By William BlairJanuary 25, 2023 | nasdaq.comAXSM April 21st Options Begin TradingFebruary 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 23, 2023 | finance.yahoo.com2 Promising New Growth Stocks to Watch in 2023January 20, 2023 | seekingalpha.comAXSM Axsome Therapeutics, Inc.January 9, 2023 | msn.com$100 Invested In This Stock 5 Years Ago Would Be Worth $1,900 TodayJanuary 7, 2023 | finance.yahoo.com2 Stocks That Could Double Your Money in 2023December 23, 2022 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)December 23, 2022 | msn.comHere's How Much $100 Invested In Axsome Therapeutics 5 Years Ago Would Be Worth TodayDecember 22, 2022 | finance.yahoo.comGot $5,000? 2 Unstoppable Stocks to Buy and HoldDecember 21, 2022 | finance.yahoo.comInstitutional investors in Axsome Therapeutics, Inc. (NASDAQ:AXSM) see US$220m decrease in market cap last week, although long-term gains have benefitted them.December 14, 2022 | seekingalpha.comTG Therapeutics: Would Santa Deliver An Early Present?December 10, 2022 | finance.yahoo.com3 High-Flying Stocks in 2022 That Should Keep Soaring in 2023December 7, 2022 | msn.comIf You Invested $100 In This Stock 5 Years Ago, You Would Have $1,500 TodayDecember 7, 2022 | seekingalpha.comAxsome's depression drug Auvelity sustains improvements in symptoms in trialDecember 7, 2022 | finance.yahoo.comGot $2,000? 3 Growth Stocks to Buy That Could Double Your MoneyDecember 7, 2022 | finance.yahoo.comAxsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual MeetingDecember 2, 2022 | finance.yahoo.comAxsome Therapeutics Stock: Bear vs. BullNovember 30, 2022 | msn.comAxsome Therapeutics's Return On Capital Employed InsightsNovember 28, 2022 | msn.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $13,000 TodayNovember 28, 2022 | marketwatch.comAxsome Therapeutics Shares Hit 52-Week High, Propelled by Alzheimer's Study >AXSMSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AXSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Axsome Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AXSM Company Calendar Last Earnings11/07/2022Today2/04/2023Next Earnings (Confirmed)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AXSM CUSIPN/A CIK1579428 Webaxsome.com Phone(212) 332-3241Fax212-320-0245Employees108Year FoundedN/APrice Target and Rating Average Stock Price Forecast$108.15 High Stock Price Forecast$210.00 Low Stock Price Forecast$75.00 Forecasted Upside/Downside+57.4%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($4.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,400,000.00 Net MarginsN/A Pretax Margin-622.89% Return on Equity-312.00% Return on Assets-90.97% Debt Debt-to-Equity Ratio0.60 Current Ratio4.19 Quick Ratio4.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.41 per share Price / Book167.56Miscellaneous Outstanding Shares43,430,000Free Float32,135,000Market Cap$2.98 billion OptionableOptionable Beta1.95 Key ExecutivesHerriott TabuteauChairman & Chief Executive OfficerMark L. JacobsonChief Operating OfficerNick PizzieChief Financial OfficerJoseph Debrah-AffulControllerAmanda JonesSenior Vice President-Clinical DevelopmentKey CompetitorsHUTCHMEDNASDAQ:HCMUltragenyx PharmaceuticalNASDAQ:RAREAbCellera BiologicsNASDAQ:ABCLACADIA PharmaceuticalsNASDAQ:ACADMirati TherapeuticsNASDAQ:MRTXView All CompetitorsInsiders & InstitutionsCannell & Co.Bought 320,680 shares on 2/3/2023Ownership: 0.852%OLD National Bancorp INSold 9,173 shares on 2/3/2023Ownership: 0.040%D.A. Davidson & CO.Sold 850 shares on 2/3/2023Ownership: 0.023%Resources Investment Advisors LLC.Sold 1,427 shares on 2/2/2023Ownership: 0.019%ProShare Advisors LLCBought 1,047 shares on 2/2/2023Ownership: 0.018%View All Institutional Transactions AXSM Stock - Frequently Asked Questions Should I buy or sell Axsome Therapeutics stock right now? 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXSM shares. View AXSM analyst ratings or view top-rated stocks. What is Axsome Therapeutics' stock price forecast for 2023? 12 Wall Street research analysts have issued 12 month target prices for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $75.00 to $210.00. On average, they anticipate the company's share price to reach $108.15 in the next year. This suggests a possible upside of 57.4% from the stock's current price. View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts. How have AXSM shares performed in 2023? Axsome Therapeutics' stock was trading at $77.13 at the beginning of the year. Since then, AXSM stock has decreased by 10.9% and is now trading at $68.70. View the best growth stocks for 2023 here. Are investors shorting Axsome Therapeutics? Axsome Therapeutics saw a increase in short interest in January. As of January 15th, there was short interest totaling 7,940,000 shares, an increase of 5.2% from the December 31st total of 7,550,000 shares. Based on an average daily volume of 1,350,000 shares, the days-to-cover ratio is presently 5.9 days. Currently, 22.4% of the shares of the company are short sold. View Axsome Therapeutics' Short Interest. When is Axsome Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our AXSM earnings forecast. How can I listen to Axsome Therapeutics' earnings call? Axsome Therapeutics will be holding an earnings conference call on Monday, February 27th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Axsome Therapeutics' earnings last quarter? Axsome Therapeutics, Inc. (NASDAQ:AXSM) issued its quarterly earnings data on Monday, November, 7th. The company reported ($1.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.10) by $0.07. The company earned $16.85 million during the quarter, compared to analyst estimates of $16.59 million. What other stocks do shareholders of Axsome Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY). When did Axsome Therapeutics IPO? (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. acted as the underwriters for the IPO and Brean Capital was co-manager. What is Axsome Therapeutics' stock symbol? Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM." Who are Axsome Therapeutics' major shareholders? Axsome Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Cannell & Co. (0.85%), Iridian Asset Management LLC CT (0.73%), Simplex Trading LLC (0.00%), Peregrine Capital Management LLC (0.22%), Hennion & Walsh Asset Management Inc. (0.21%) and Lindbrook Capital LLC (0.19%). Insiders that own company stock include Mark Coleman, Mark E Saad, Nick Pizzie and Roger Jeffs. View institutional ownership trends. How do I buy shares of Axsome Therapeutics? Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Axsome Therapeutics' stock price today? One share of AXSM stock can currently be purchased for approximately $68.70. How much money does Axsome Therapeutics make? Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $2.98 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($4.06) on an earnings per share basis. How many employees does Axsome Therapeutics have? The company employs 108 workers across the globe. How can I contact Axsome Therapeutics? Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245. This page (NASDAQ:AXSM) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.